Include

Exclude

• Quantitative measures of acceptability and feasibility, such as the following:  ◦ Completeness of data collection (e.g. percentage of days per week period with data available, percentage of sensors returned)  ◦ Patient-reported measures of acceptability, including measures of treatment satisfaction (e.g. questionnaires)  ◦ Number (or percentage) of participants declining CGM  ◦ Studies stopping early, e.g. due to recruitment issues • Qualitative data relating to the experience of using CGM from a service user, carer, and/or healthcare professional perspective in a research and/or clinical practice context

• Quantitative studies not reporting any feasibility or acceptability data, e.g.:  ◦ Studies reporting only clinical diabetes outcomes (e.g. impact on HbA1c)  ◦ Studies reporting outcomes like quality of life, diabetes burden, or adverse events that are not direct measures of acceptability (e.g. adverse skin reactions or infections) • Qualitative studies exploring the lived experience of individuals with diabetes, their carers, and/or healthcare professionals more broadly without a direct focus on CGM